CORCencora
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- $4.66Beat
- vs $4.56 expected on Nov 4
- Stock move on it
- +3.96%
- one session
- Typical move
- ±3.8%
- average over 2 reports
- Price
- $349.36
- −0.15% today · $59.0B cap
Past and upcoming reports
2
| Nov 4, 2026 | Sep 30, 2026 | Time not given | $4.56 | Beat$4.66 | +3.96% |
| Aug 5, 2026 | Jun 30, 2026 | Time not given | $4.38 | Beat$4.48 | +3.57% |
After the report
Aug 5, 2026 report
This covers the Aug 5, 2026 report. The Nov 4, 2026 numbers are in the table above.
Cencora beat quarterly EPS, but the stock fell 1.39% as margin and execution risks remained unresolved
Cencora reported fiscal third-quarter EPS of $4.48, beating $4.37 estimates by 2.5%. Management raised its outlook, while the stock closed at $320.48 on August 7, down $4.53, or 1.39%, from the prior close. The forward thesis depends on executing the raised outlook despite 1.3% operating margins, 3.65 debt-to-equity, and risks involving specialty demand and narrow margins.
Reported against expected
BeatReported EPS was $4.48 for the quarter ended June 30, versus a $4.37 estimate. the 2.5% surprise was a beat.
Guidance
RaisedManagement raised its outlook. the payload does not provide the revised guidance value or specific financial targets.
How the stock reacted
The stock closed at $320.48 on August 7, down $4.53, or 1.39%, versus the previous close. event-day and day-1/day-2 reaction data were unavailable.
What changed
Cencora reported $4.48 EPS, beating the $4.37 estimate by 2.5%, while management raised its outlook.
What the price now assumes
The August 7 decline to $320.48 suggests investors discounted the beat amid 1.3% operating margins and execution risk.
What it means for the business
Maintain a constructive bias only if raised-outlook execution improves margins or specialty demand without worsening 3.65 debt-to-equity leverage.
The next one to three months, as we saw it then
Better case50%
Raised-outlook execution and continued EPS growth support the constructive thesis despite the post-report decline.
Worse case50%
The EPS beat proves insufficient if low margins, specialty-demand weakness, or leverage prevent delivery of the raised outlook.
If you hold it
Hold unless the next reported period shows another earnings shortfall, outlook deterioration, or operating margins remaining near 1.3% with worsening leverage.
If you are watching
Add only if the next reported period confirms the raised outlook and shows margin improvement. do not trade if outlook execution and specialty-demand trends remain undisclosed.
Scenario odds are a judgement, not measured.